The ISRS began a serie of Webinars, starting October 11th, 2016.
These Webinars are organized through a specific online service. If you wish to attend these sessions, you will be asked to register first, but you also need to have a device (computer, smartphone, tablet) that meets specific requirements. Click here to check your system
After the webinar, a video replay is made available to ISRS members.
March 09, 2018
SBRT for Oligometastatic disease by Marta SCORSETTI
12:00 pm (Dublin, Edinburgh, Lisbon, London) - 1:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 9:00 am (Brasilia) - 9:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 10:00pm (Brisbane)
SBRT in oligometastatic patients is an extremely exciting topic, as it may represent a fantastic opportunity to improve cancer patients' prognosis and also to possibly cure some of them. I will try to define who is the oligometastatic patient and I will show what evidence we currently have of local ablative approaches integrating the traditional systemic therapies. I will also talk about what challenges we are facing at the moment and that we need to address in the near future, to be able to benefit from this new approach.
April 05, 2018
Strategies of Sharpening Dose Fall-off for Stereotactic Radiosurgery of Brain Lesions by Lijun MA
1:00 pm (Dublin, Edinburgh, Lisbon, London) - 2:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 9:00 am (Brasilia) - 9:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 10:00pm (Brisbane)
A sharp dose fall-off is the hall-mark of intracranial stereotactic radiosurgery (SRS). This dosimetric feature had enabled high-dose focal radiation to be safely and effectively delivered toward a single or multiple brain lesions in one or few treatments. In this presentation, I will highlight physical principles, user strategies as well as some historical endeavors and controversies in quantifying and enhancing the dose fall-off for SRS of simple and complex brain lesions. On-going developments and emerging technologies related to the topic will be also discussed.